



SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	01948/088004
		Serial No.	10/624,809
		Applicant	Karumanchi et al.
		Filing Date	July 21, 2003
		Group	1647
		IDS Filed	October 24, 2007

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date / Date Filed	Patentee or Applicant
	10/920,116	Aug. 16, 2004	Thadhani et al. (Pending Application)
	10/947,791	Sep. 23, 2004	Thadhani et al. (Pending Application)
	2005/0148023	Jul. 7, 2005	Thadhani et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	EP 1417971	May 12, 2004	European Patent Office	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Baker et al., "Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia," <i>Obstet. Gynecol.</i> 86: 815-821 (1995).
	Davis-Smyth et al., "The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade," <i>EMBO J.</i> 15: 4919-4927 (1996).
	Davis-Smyth et al., "Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability," <i>J. Biol. Chem.</i> 273: 3216-3222 (1998).
	Dvorak, "Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy," <i>J. Clin. Oncol.</i> 20: 4368-4380 (2002).
	Errico et al., "Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor," <i>J. Biol. Chem.</i> 279: 43929-43939 (2004).
	Ferrara et al., "Role of vascular endothelial growth factor in regulation of physiological angiogenesis," <i>Am. J. Physiol. Cell Physiol.</i> 280: C1358-C1366 (2001).
	Ferrara et al., "The biology of VEGF and its receptors," <i>Nat. Med.</i> 9: 669-676 (2003).

EXAMINER /Ian Dang/	DATE CONSIDERED 12/19/2007
---------------------	----------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.D./

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	01948/088004
	Serial No.	10/624,809
	Applicant	Karumanchi et al.
	Filing Date	July 21, 2003
	Group	1647
	IDS Filed	October 24, 2007

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Hsieh, Tsang-Tang, "Maternal serum placenta growth factor and vascular endothelial growth factor in pregnancies complicated by preeclampsia," <i>Am. J. Obstet. Gynecol.</i> 184: S70 (2001). (Abstract)
	Iyer et al., "The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 Å resolution," <i>J. Biol. Chem.</i> 276: 12153-12161. 2001
	Keyt et al., "Identification of vascular endothelial growth factor determinants for binding KDR and Flt-1 receptors," <i>J. Biol. Chem.</i> 271: 5638-5646 (1996).
	Krussel et al., "Expression of mRNA for vascular endothelial growth factor transmembraneous receptors Flt1 and KDR, and the soluble receptor sflt in cycling human endometrium," <i>Mol. Hum. Reprod.</i> 5: 452-458 (1999).
	Li et al., "Recombinant VEGF121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia," <i>Hypertension</i> 092098 (2007).
	Lyll et al., "Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia," <i>BJOG</i> 104: 223-228 (1997).
	Maynard et al., "sFlt-1, a circulating VEGF antagonist, is up-regulated in preeclampsia and contributes to endothelial dysfunction," <i>J. Am. Soc. Nephrol.</i> 13: SU-FC280 (2002).
	Muller et al., "Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site," <i>Proc. Natl. Acad. Sci. USA</i> 94: 7192-7197 (1997).
	Muller et al., "The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 Å resolution: multiple copy flexibility and receptor binding," <i>Structure</i> 5: 1325-1338 (1997).
	Olofsson et al., "Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells," <i>Proc. Natl. Acad. Sci. USA</i> 95: 11709-11714 (1998).
	Park et al., "Placenta growth factor potentiation of vascular endothelial growth factor bioactivity, <i>in vitro</i> and <i>in vivo</i> , and high affinity binding to Flt-1 but not to Flk-1/KDR," <i>J. Biol. Chem.</i> 269: 25646-25654 (1994).
	Park et al., "An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia," <i>Am. J. Obstet. Gynecol.</i> 193: 984-989. 2005
	Polliotti et al., "Second trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia," <i>Obstet. Gynecol.</i> 101: 1266-1274 (2003)
	Powers et al., "Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia," <i>Am. J. Obstet. Gynecol.</i> 193: 185-191 (2005).
	Reuvekamp et al., "Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia," <i>BJOG</i> 106: 1019-1022 (1999).

EXAMINER /lan Dang/	DATE CONSIDERED 12/19/2007
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /LD/	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	01948/088004
	Serial No.	10/624,809
	Applicant	Karumanchi et al.
	Filing Date	July 21, 2003
	Group	1647
	IDS Filed	October 24, 2007

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Sawano et al., "Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor," <i>Cell Growth Differ.</i> 7: 213-221 (1996).
	Vuorela, "Vascular endothelial growth factor, its receptors, and the Tie receptor in normal and complicated pregnancy," Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, University of Helsinki, Finland (2000).
	Walsh et al., "Computer modeling of the receptor-binding domains of VEGF and PlGF," <i>Protein Eng.</i> 10: 389-398 (1997).
	Wiesmann et al., "Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor," <i>Cell</i> 91: 695-704 (1997).
	European Search Report dated May 23, 2007 (PCT/US0322892).
	Office Action for U.S.S.N. 10/771,518 mailed on June 23, 2006.
	Office Action for U.S.S.N. 10/771,518 mailed on March 8, 2007.
	Office Action for U.S.S.N. 11/019,559 mailed on June 6, 2006.
	Office Action for U.S.S.N. 11/019,559 mailed on March 22, 2007.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //I.D./

EXAMINER /lan Dang/	DATE CONSIDERED 12/19/2007
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //I.D./	